Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer.

Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer. 2008 May 20; 98(10):1608-13.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Carcinoma, Non-Small-Cell Lung
Drug Administration Schedule
Female
Humans
Lung Neoplasms
Male
Middle Aged
Neoplasm Staging
Paclitaxel
Patient Selection
Polyglutamic Acid
Quality of Life
Taxoids
Treatment Outcome

authors with profiles

Philip Bonomi